Skip to main content
. 2017 Aug 1;3(1):58–65. doi: 10.1089/pancan.2017.0011

FIG. 1.

FIG. 1.

Treatment study regimen for IA treatment. Cycle 1 started at the lowest dose of gemcitabine (250 mg/m2). Subsequent cycles were dose escalated by 250 mg/m2 each cycle if a DLT was not experienced during that cycle, up to a maximum dose of 1000 mg/m2. *Starting with the ninth enrolled patient, the dose for the first cycle increased to 500 mg/m2. DLT, dose-limiting toxicity; IA, intra-arterial.